# Mobix Labs, Inc: financial statements, quarterly

MOBX · Nasdaq · CIK 1855467 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/mobx.md) · [Financials](/companies/mobx/financials.md) · [Filings](/companies/mobx/filings.md) · [Insiders](/companies/mobx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mobx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4 d](/filings/0001493152-24-051917.md) | [0.3](/filings/0001493152-25-006122.md) | [1.1](/filings/0001641172-25-010986.md) | [2.1](/filings/0001493152-25-011909.md) | [3.0 d](/filings/0001493152-26-001921.md) | [3.2](/filings/0001493152-26-006406.md) | [2.5](/filings/0001493152-26-024661.md) | [2.4](/filings/0001493152-26-038848.md) | [1.9 d](/filings/0001493152-26-001921.md) | [1.9](/filings/0001493152-26-006406.md) | [1.0](/filings/0001493152-26-024661.md) | [0.8](/filings/0001493152-26-038848.md) |
| Cost of revenue | $m | [0.4 d](/filings/0001493152-24-051917.md) | [0.3](/filings/0001493152-25-006122.md) | [1.0](/filings/0001641172-25-010986.md) | [1.3](/filings/0001493152-25-011909.md) | [1.3 d](/filings/0001493152-26-001921.md) | [1.5](/filings/0001493152-26-006406.md) | [1.5](/filings/0001493152-26-024661.md) | [1.0](/filings/0001493152-26-038848.md) | [0.9 d](/filings/0001493152-26-001921.md) | [1.3](/filings/0001493152-26-006406.md) | [0.8](/filings/0001493152-26-024661.md) | [0.7](/filings/0001493152-26-038848.md) |
| Gross profit | $m | not reported | [(0.0)](/filings/0001493152-25-006122.md) | [0.2](/filings/0001641172-25-010986.md) | [0.7](/filings/0001493152-25-011909.md) | [1.7 d](/filings/0001493152-26-001921.md) | [1.7](/filings/0001493152-26-006406.md) | [1.0](/filings/0001493152-26-024661.md) | [1.3](/filings/0001493152-26-038848.md) | [1.0 d](/filings/0001493152-26-001921.md) | [0.6](/filings/0001493152-26-006406.md) | [0.2](/filings/0001493152-26-024661.md) | [0.1](/filings/0001493152-26-038848.md) |
| Research and development | $m | [1.8 d](/filings/0001493152-24-051917.md) | [1.6](/filings/0001493152-25-006122.md) | [1.4](/filings/0001641172-25-010986.md) | [1.4](/filings/0001493152-25-011909.md) | [1.5 d](/filings/0001493152-26-001921.md) | [0.6](/filings/0001493152-26-006406.md) | [0.7](/filings/0001493152-26-024661.md) | [0.5](/filings/0001493152-26-038848.md) | [0.6 d](/filings/0001493152-26-001921.md) | [0.4](/filings/0001493152-26-006406.md) | [0.4](/filings/0001493152-26-024661.md) | [0.4](/filings/0001493152-26-038848.md) |
| Selling, general and administrative | $m | [0.0](/filings/0001410578-23-002479.md) | [15.7](/filings/0001493152-25-006122.md) | [7.4](/filings/0001641172-25-010986.md) | [8.7](/filings/0001493152-25-011909.md) | [10.1 d](/filings/0001493152-26-001921.md) | [15.7](/filings/0001493152-26-006406.md) | [8.1](/filings/0001493152-26-024661.md) | [8.2](/filings/0001493152-26-038848.md) | [7.5 d](/filings/0001493152-26-001921.md) | [9.0](/filings/0001493152-26-006406.md) | [5.8](/filings/0001493152-26-024661.md) | [7.0](/filings/0001493152-26-038848.md) |
| Operating income | $m | [(0.2)](/filings/0001410578-23-002479.md) | [(17.3)](/filings/0001493152-25-006122.md) | [(8.6)](/filings/0001641172-25-010986.md) | [(9.3)](/filings/0001493152-25-011909.md) | [(11.2) d](/filings/0001493152-26-038848.md) | [(14.6)](/filings/0001493152-26-006406.md) | [(7.8)](/filings/0001493152-26-024661.md) | [(8.1)](/filings/0001493152-26-038848.md) | [(7.2) d](/filings/0001493152-26-038848.md) | [(8.8)](/filings/0001493152-26-006406.md) | [(6.1)](/filings/0001493152-26-024661.md) | [(7.4)](/filings/0001493152-26-038848.md) |
| Interest expense | $m | [2.2 d](/filings/0001493152-24-051917.md) | [0.9](/filings/0001213900-24-015301.md) | [0.2](/filings/0001213900-24-043589.md) | [0.1](/filings/0001493152-25-011909.md) | [0.4 d](/filings/0001493152-26-001921.md) | [0.2](/filings/0001493152-26-006406.md) | [0.3](/filings/0001493152-26-024661.md) | [0.5](/filings/0001493152-26-038848.md) | [1.3 d](/filings/0001493152-26-001921.md) | [1.4](/filings/0001493152-26-006406.md) | [1.4](/filings/0001493152-26-024661.md) | [0.9](/filings/0001493152-26-038848.md) |
| Income tax | $m | [0.0 d](/filings/0001493152-24-051917.md) | [(1.3)](/filings/0001493152-25-006122.md) | [(0.0)](/filings/0001641172-25-010986.md) | [(1.5)](/filings/0001493152-25-011909.md) | [0.4 d](/filings/0001493152-26-001921.md) | [(0.0)](/filings/0001493152-26-006406.md) | [(0.0)](/filings/0001493152-26-024661.md) | [(0.0)](/filings/0001493152-26-038848.md) | [0.0 d](/filings/0001493152-26-001921.md) | [(0.0)](/filings/0001493152-26-006406.md) | [0.0](/filings/0001493152-26-024661.md) | [0.0](/filings/0001493152-26-038848.md) |
| Net income | $m | [(0.0)](/filings/0001410578-23-002479.md) | [0.9](/filings/0001493152-25-011909.md) | [(1.8)](/filings/0001493152-25-011909.md) | [(7.7)](/filings/0001493152-25-011909.md) | [(11.5) d](/filings/0001493152-26-001921.md) | [(19.8)](/filings/0001493152-26-038848.md) | [(2.3)](/filings/0001493152-26-038848.md) | [(8.3)](/filings/0001493152-26-038848.md) | [(15.7) d](/filings/0001493152-26-001921.md) | [(10.1)](/filings/0001493152-26-038848.md) | [(5.9)](/filings/0001493152-26-038848.md) | [(16.8)](/filings/0001493152-26-038848.md) |
| Diluted EPS | $ per share | not reported | [0.04](/filings/0001493152-25-006122.md) | [(0.21)](/filings/0001641172-25-010986.md) | [(0.25)](/filings/0001493152-25-011909.md) | not reported | [(0.52)](/filings/0001493152-26-006406.md) | [(0.57)](/filings/0001493152-26-024661.md) | [(1.70)](/filings/0001493152-26-038848.md) | not reported | [(0.16)](/filings/0001493152-26-006406.md) | [(0.59)](/filings/0001493152-26-024661.md) | [(1.33)](/filings/0001493152-26-038848.md) |
| Basic EPS | $ per share | not reported | [0.04](/filings/0001493152-25-006122.md) | [(0.09)](/filings/0001641172-25-010986.md) | [(0.25)](/filings/0001493152-25-011909.md) | not reported | [(0.52)](/filings/0001493152-26-006406.md) | [(0.57)](/filings/0001493152-26-024661.md) | [(1.70)](/filings/0001493152-26-038848.md) | not reported | [(0.16)](/filings/0001493152-26-006406.md) | [(0.59)](/filings/0001493152-26-024661.md) | [(1.33)](/filings/0001493152-26-038848.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001410578-23-002479.md) | [14.8](/filings/0001213900-24-015301.md) | [3.0](/filings/0001213900-24-043589.md) | [0.2](/filings/0001213900-24-068993.md) | [0.3](/filings/0001493152-26-001921.md) | [0.4](/filings/0001493152-25-006122.md) | [0.8](/filings/0001641172-25-010986.md) | [0.2](/filings/0001493152-25-011909.md) | [3.3](/filings/0001493152-26-038848.md) | [0.3](/filings/0001493152-26-006406.md) | [2.6](/filings/0001493152-26-024661.md) | [2.1](/filings/0001493152-26-038848.md) |
| Current assets | $m | [0.8](/filings/0001493152-24-051917.md) | [15.9](/filings/0001213900-24-015301.md) | [4.4](/filings/0001213900-24-043589.md) | [4.1](/filings/0001213900-24-068993.md) | [5.3](/filings/0001493152-26-001921.md) | [3.8](/filings/0001493152-25-006122.md) | [4.0](/filings/0001641172-25-010986.md) | [3.7](/filings/0001493152-25-011909.md) | [6.7](/filings/0001493152-26-038848.md) | [2.9](/filings/0001493152-26-006406.md) | [5.5](/filings/0001493152-26-024661.md) | [6.0](/filings/0001493152-26-038848.md) |
| Total assets | $m | [18.7](/filings/0001493152-24-051917.md) | [41.5](/filings/0001213900-24-015301.md) | [29.5](/filings/0001213900-24-043589.md) | [41.3](/filings/0001213900-24-068993.md) | [39.1](/filings/0001493152-26-001921.md) | [37.3](/filings/0001493152-25-006122.md) | [36.5](/filings/0001641172-25-010986.md) | [34.6](/filings/0001493152-25-011909.md) | [37.1](/filings/0001493152-26-038848.md) | [32.7](/filings/0001493152-26-006406.md) | [34.9](/filings/0001493152-26-024661.md) | [34.9](/filings/0001493152-26-038848.md) |
| Current liabilities | $m | [20.4](/filings/0001493152-24-051917.md) | [21.4](/filings/0001213900-24-015301.md) | [18.0](/filings/0001213900-24-043589.md) | [25.5](/filings/0001213900-24-068993.md) | [26.1](/filings/0001493152-26-001921.md) | [28.4](/filings/0001493152-25-006122.md) | [31.5](/filings/0001641172-25-010986.md) | [26.7](/filings/0001493152-25-011909.md) | [27.8](/filings/0001493152-26-038848.md) | [25.2](/filings/0001493152-26-006406.md) | [24.0](/filings/0001493152-26-024661.md) | [22.1](/filings/0001493152-26-038848.md) |
| Total liabilities | $m | [21.8](/filings/0001493152-24-051917.md) | [37.1](/filings/0001213900-24-015301.md) | [25.3](/filings/0001213900-24-043589.md) | [32.7](/filings/0001213900-24-068993.md) | [33.6](/filings/0001493152-26-001921.md) | [40.3](/filings/0001493152-25-006122.md) | [36.2](/filings/0001641172-25-010986.md) | [34.1](/filings/0001493152-25-011909.md) | [37.4](/filings/0001493152-26-038848.md) | [28.1](/filings/0001493152-26-006406.md) | [26.0](/filings/0001493152-26-024661.md) | [26.7](/filings/0001493152-26-038848.md) |
| Long-term debt | $m | [6.6](/filings/0001493152-24-051917.md) | [5.0](/filings/0001213900-24-015301.md) | [3.2](/filings/0001213900-24-043589.md) | [3.2](/filings/0001213900-24-068993.md) | [1.3](/filings/0001493152-26-001921.md) | [0.9](/filings/0001493152-25-006122.md) | [0.6](/filings/0001641172-25-010986.md) | [1.4](/filings/0001493152-25-011909.md) | [1.1](/filings/0001493152-26-038848.md) | [1.9](/filings/0001493152-26-006406.md) | [1.0](/filings/0001493152-26-024661.md) | [2.4](/filings/0001493152-26-038848.md) |
| Current portion of debt | $m | [6.6](/filings/0001213900-24-068993.md) | [5.0](/filings/0001213900-24-015301.md) | [3.2](/filings/0001213900-24-043589.md) | [3.2](/filings/0001213900-24-068993.md) | [2.1](/filings/0001493152-26-001921.md) | [2.7](/filings/0001493152-25-006122.md) | [4.0](/filings/0001641172-25-010986.md) | [3.0](/filings/0001493152-25-011909.md) | [5.1](/filings/0001493152-26-038848.md) | [4.3](/filings/0001493152-26-006406.md) | [5.4](/filings/0001493152-26-024661.md) | [2.4](/filings/0001493152-26-038848.md) |
| Shareholders' equity | $m | [(5.3)](/filings/0001493152-26-001921.md) | [4.4](/filings/0001493152-25-011909.md) | [4.2](/filings/0001493152-25-011909.md) | [8.5](/filings/0001493152-25-011909.md) | [5.5](/filings/0001493152-26-038848.md) | [(3.0)](/filings/0001493152-26-038848.md) | [0.3](/filings/0001493152-26-038848.md) | [0.4](/filings/0001493152-26-038848.md) | [(0.3)](/filings/0001493152-26-038848.md) | [4.7](/filings/0001493152-26-038848.md) | [8.8](/filings/0001493152-26-038848.md) | [6.2](/filings/0001493152-26-038848.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.6) d](/filings/0001493152-24-051917.md) | [(3.6)](/filings/0001493152-25-006122.md) | [(8.1) d](/filings/0001641172-25-010986.md) | [(3.1) d](/filings/0001493152-25-011909.md) | [33.2 d](/filings/0001493152-26-038848.md) | [(0.9)](/filings/0001493152-26-006406.md) | [(0.6) d](/filings/0001493152-26-024661.md) | [(4.1) d](/filings/0001493152-26-038848.md) | [15.7 d](/filings/0001493152-26-038848.md) | [(4.8)](/filings/0001493152-26-006406.md) | [(4.3) d](/filings/0001493152-26-024661.md) | [(5.7) d](/filings/0001493152-26-038848.md) |
| Capital expenditure | $m | not reported | [0.1](/filings/0001493152-25-006122.md) | [1.0 d](/filings/0001641172-25-010986.md) | [(0.0) d](/filings/0001493152-25-011909.md) | [(1.0) d](/filings/0001493152-26-001921.md) | not reported | not reported | [0.0 d](/filings/0001493152-26-038848.md) | [0.0 d](/filings/0001493152-26-001921.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.4](/filings/0001213900-24-015301.md) | [14.0](/filings/0001213900-24-043589.md) | [15.3](/filings/0001213900-24-068993.md) | [23.3](/filings/0001493152-25-006122.md) | [29.2](/filings/0001641172-25-010986.md) | [30.6](/filings/0001493152-25-011909.md) | [38.4](/filings/0001493152-26-006406.md) | [4.0](/filings/0001493152-26-024661.md) | [4.9](/filings/0001493152-26-038848.md) | [63.1](/filings/0001493152-26-006406.md) | [9.8](/filings/0001493152-26-024661.md) | [12.6](/filings/0001493152-26-038848.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,778,912 at 2023-11-14, from the cover of the [10-Q filed 2023-11-14](/filings/0001410578-23-002479.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.